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ohamed_mounir2Abstract A simple, rapid, accurate and highly sensitive spectroﬂuorimetric method has been
developed for determination of some angiotensin II receptor antagonists (AIIRA’s), namely
Losartan potassium (Los-K), Irbesartan (Irb), Valsartan (Val) and Candesartan cilexetil (Cand) in
pure forms as well as in their pharmaceutical dosage forms. All the variables affecting the relative
ﬂuorescence intensity (RFI) were studied and optimized. Under the optimum conditions, linear
relationships with good correlation coefﬁcients (0.9982–0.9991) were obtained over the concentra-
tion range from 0.006 mg/mL to 1.7 mg/mL. Good accuracy and precision were successfully
obtained for the analysis of tablets containing each drug alone or combined with hydrochlor-
othiazide (HCTZ) without interferences from the co-formulated HCTZ or the additives commonly
present in tablets.
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000@yahoo.com1. Introduction
Angiotensin II receptor antagonists (AIIRA’s) are orally
effective potent antihypertensive drugs that selectively block-
ing AT1 receptors in many tissues leading to marked decrease
in angiotensin II synthesis which is potent vasoconstrictor and
then lowering the blood pressure [1]. The investigated drugs
were Losartan potassium (Los-K), Irbesartan (Irb), Valsartan
(Val) and Candesartan cilexetil (Cand) (Fig. 1).
The studied drugs have been approved by FDA since the end
of 1990s and are prescribed as the ﬁrst line treatment of
hypertension, left ventricular hypertrophy, nephropathy in type
2 diabetic patients and heart failure [2]. Recently they became
ofﬁcial in the USP 2007 [3], only Losartan potassium is ofﬁcial in
the BP 2010 [4] while Cand is not ofﬁcial in any pharmacopeia.
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Figure 1 Chemical structure of the studied drugs.
Spectroﬂuorimetry for determination of AIIRA’s 13Several methods have been reported for the analysis of the
investigated AIIRA’s, including high performance liquid
chromatography [5–9], high pressure thin layer chromatogra-
phy [10–12], capillary electrophoresis [13–15], voltammetric
methods [16–19] and spectrophotometric methods [20–25].
The presence of different ﬂuorescent functional groups (ﬂuor-
ophores) such as biphenyl, tetrazole and/or imidazole in the
chemical structures of the investigated drugs allowed their
determination by measurements of its native ﬂuorescence. Limited
spectroﬂuorimetric methods were found in the literatures regard-
ing the analysis of Los-K [26], Irb [27] and Val [28] depending on
their native ﬂuorescence. Also, spectroﬂuorimetry was reported
for determination of the pKa value of all the investigated drugs
[29]. Unfortunately, all these previously reported methods did not
establish complete study for determination of the ﬂuorescence of
these drugs as well as lack of sensitivity was noticed in all cases.
So it is deemed necessary to enhance the sensitivity of the native
ﬂuorescence of the investigated drugs.
It is well known that, the relative ﬂuorescence intensity of
any chemical compound is greatly affected by different
solvents, acids, bases, pH or even temperature. The presence
of tetrazole ring (pKa of tetrazole 5) is responsible for the
acidic properties of the cited drugs as well as, its pKa values,
which are 3.15, 4.70, 4.90 and 6.00 for Los-K, Irb, Val and
Cand, respectively [29] so it is clear that, for maximum
determination of the native ﬂuorescence of these drugs with
the highest sensitivity, the RFI should be measured in acids or
acidic medium. All these aforementioned factors drew our
attention to use different acids, bases and buffers to develop a
highly sensitive, simple, rapid and reproducible spectroﬂouri-
metric method for determination of Los-K, Irb, Val and Cand
based on measurement of their native ﬂuorescence in pure
forms and pharmaceutical formulations.
2. Experimental
2.1. Apparatus
Spectroﬂuorophotometer RF-5301 PC (Shimadzu, Tokyo,
Japan) was used with the excitation and emission slit control
set at slit width 5 mm equipped with 1 cm quartz cell.Sartorius handy balance-H51 was obtained from GmbH
Gottingen, Germany. Milwaukee SM 101 pH meter and
MLW type thermostatically controlled water bath, which
was obtained from Memmert GmbH, Schwabach, Germany.
2.2. Materials and reagents
All solvents and reagents used were of analytical grade.
Losartan potassium (Los-K) (Amriya Pharmaceutical Indus-
tries, Alexandria, Egypt), Irbesartan (Irb) (Memphis Pharm.
Co, Cairo, Egypt), Valsartan (Val) (G.N.P. Pharm. Co, 6th of
October, Egypt) and Candesartan cilexetil (Cand) (Pharoania
Pharmaceutical Corroboration) were obtained as a gift and
used as supplied.
Hydrochloric acid (0.1 M and 0.5 M), phosphoric acid
(0.1 M), citric acid (0.1 M), NaOH (0.1 M) and Teorell and
Stenhagen buffer (pH 2.0–7.0) [30] were prepared using double
distilled water. Pharmaceutical formulations (Tablets) con-
taining the studied drugs were purchased from a local market.
Losarmephas (Sigma Pharm.Co., Cairo, Egypt) and Hysar-
tans (Amriya Pharm. Ind. Co., Alexanderia, Egypt), which
are labeled to contain 50 mg Los-K or 50 mg Los-K and
12.5 mg hydrochlorothiazide (HCTZ), respectively, Aprovels
and Co-Aprovels (Sanoﬁ Winthrop, France), which are
labeled to contain 300 mg Irb or 300 mg Irb and 12.5 mg
HCTZ, respectively, Taregs and Co-Taregs (Novartis
Pharm., Cairo, Egypt), which are labeled to contain 80 mg
Val or 160 mg Val and 12.5 mg HCTZ, respectively, Atacands
and Atacand pluss (Astra-Zenica, 6th October, Egypt), which
are labeled to contain 8 mg Cand or 8 mg Cand and 12.5 mg
HCTZ, respectively.
2.3. Preparation of standard solutions
An accurately weighed amount (10 mg) of Los-K, Irb, Val or
Cand was transferred into 25 mL volumetric ﬂasks, dissolved
and completed to the volume with methanol to obtain the
stock standard solutions for each drug. The working standard
solutions of the studied drugs were prepared by further
dilutions of suitable volumes of the stock solution with
methanol to obtain the concentrations ranged from 0.25 to
S.R. El-Shaboury et al.1410 mg/mL for either Los-K or Irb, 0.06 to 6.50 mg/mL for Val
and 0.5 to 17 mg/mL for Cand.
2.4. Preparation of sample solutions
Ten tablets of each formulation containing Los-K, Irb, Val or
Cand alone or combined with HCTZ were accurately weighed
and ﬁnely powdered. An accurately weighed quantity of the
powdered tablets equivalent to 10 mg of each studied drug was
transferred into different 25 mL volumetric ﬂasks, dissolved in
about 10 mL methanol, sonicated for 15 min and then com-
pleted to the mark with methanol. The resulting solutions were
ﬁltered and the ﬁrst portion of the ﬁltrate was rejected. A
suitable aliquot of the obtained solutions was quantitatively
diluted with methanol to obtain concentrations within the
linear range of each studied drug as mentioned under
preparation of standard solutions.
2.5. General procedure
Accurately measured 1.0 mL of the working solutions of each
drug was transferred into separate 10 mL volumetric ﬂasks.
The solutions were completed to the volume with Teorell and
Stenhagen buffer at pH 2.3 for Los-K, pH 3.5 for Cand or
0.5 M HCl for both Irb and Val. The relative ﬂuorescence
intensity (RFI) was measured at lEx/lEm equal to 260/390 nm,
262/410 nm, 258/430 nm and 260/389 nm for Los-K, Irb, Val
and Cand, respectively, against blank treated similarly.3. Results and discussion
Initial investigations have been made to show the excitation
and emission wavelengths of each studied drug using different
solvents with different polarities such as water, acetonitrile,
ethanol, methanol and propan-2-ol. As can be seen from
Table 1 each studied drug is being absorbed in the interfering
UV area showing excitation wavelengths ranged from 231 to
262 nm and relatively considerable ﬂuorescence with emission
wavelengths in the range of 377–430 nm. It has been found
that, the ﬂuorescence of all studied drugs was increased upon
using water as solvent and decreased by decreasing the solvent
polarity. Furthermore, it was observed that, the position of the
excitation wavelengths showed hypsochromic shift for all
investigated drugs in all studied solvents accompanied by
either hypsochromic or bathochromic shifts of their emission
wavelengths.Table 1 Effect of different solvents on the relative ﬂuorescence
Solvent Solvent polarity Los-K (0.5 lg/mL) Cand
kEx/kEm RFI
a kEx/kE
Water 9.0 260/390 91 258/3
Acetonitrile 5.8 237/394 85 245/3
Ethanol 5.2 239/392 80 247/3
Methanol 5.1 241/394 79 241/3
Propan-2-ol 4.0 231/412 62 238/3
aAverage of three determinations.3.1. Optimization of the variables
The effects of acids, bases, buffers, temperature and time were
optimized to achieve maximum native ﬂuorescence for all
investigated drugs.3.1.1. Effect of acids and bases
Different acids such as HCl, citric acid, acetic acid, sulfuric
acid, nitric acid, oxalic acid and phosphoric acid (0.1 M) in
addition to bases such as NaOH and KOH (0.1 M) were used
to study their effects on the ﬂuorescence intensity for each
studied drug. Experiments showed substantial decrease in the
ﬂuorescence of all investigated drugs upon using NaOH or
KOH (0.1 M), thus all alkalis were excluded from this study.
In the case of acids, the highest ﬂuorescence intensity was
obtained on using 0.1 M citric acid for both Los-K and Cand.
On the other hand, Irb and Val gave maximum ﬂuorescence
intensity when 0.1 M HCl was used as a milieu for their
determination (Table 2). When other acids were used, the
relative ﬂuorescence intensity of all studied drugs was
obviously decreased rather than citric acid or HCl and so,
citric acid was chosen as the best acid for measurement of the
ﬂuorescence intensity for both Los-K and Cand while HCl was
selected for determination of Irb and Val.3.1.2. Effect of acid concentration
Different concentrations of HCl and citric acid (0.1–1 M) were
tried in order to select the proper acid concentration to give
maximum ﬂuorescence intensity for determination of these
drugs. It was observed that, no effect on the intensity of
ﬂuorescence for both Los-K and Cand upon using different
concentrations of citric acid (0.1–1 M). On the other hand, the
ﬂuorescence intensity of Irb and Val slightly increased by
increasing concentration of HCl till 0.3 M and then remained
constant up to 1 M. Accordingly, the best selected concentration
of HCl for determination of either Irb or Val was achieved using
0.5 M HCl.3.1.3. Effect of pH
Trials have been made to enhance the native ﬂuorescence
intensity for the studied drugs by proper choice of the pH
medium instead of acids. Different buffer systems with various
pH values and different constitution in the acidic pH range
were used to study the effect of buffer systems on the
ﬂuorescence intensity.intensity (RFI) of the investigated AIIRA’s.
(0.8 lg/mL) Irb (0.5 lg/mL) Val (0.2 lg/mL)
m RFI
a kEx/kEm RFI
a kEx/kEm RFI
a
89 193 262/410 123 258/430 125
77 190 247/422 105 249/399 98
82 188 246/411 92 256/402 91
87 187 243/413 90 252/400 90
81 173 233/391 62 232/388 83
Table 2 Effect of different acids (0.1 M) on the relative ﬂuorescence intensity (RFI) of the studied drugs.
Acid (0.1 M) RFIa
Los-K (0.5 lg/mL) Cand (0.8 lg/mL) Irb (0.5 lg/mL) Val (0.2 lg/mL)
HCl 389 167 412 295
Citric acid 408 280 252 88
Acetic acid 183 200 111 224
Sulfuric acid 305 193 376 200
Nitric acid 288 131 357 265
Oxalic acid 89 183 97 114
Phosphoric acid 383 149 232 211
aAverage of three determinations.
Spectroﬂuorimetry for determination of AIIRA’s 15Since Los-K and Cand in citric acid (0.1–1 M) and Irb and
Val in HCl (0.5 M) showed high native ﬂuorescence intensities,
it was anticipated that, buffer systems with lower pH value in
the neighborhood to the pH values of the aforementioned
acids would give the same results.
Teorell and Stenhagen buffer (0.1 M citric acid, 0.1 M
phosphoric acid, 0.1 M HCl and 0.1 M NaOH) (pH 2.0–7.0)
[30] with various pH values was tried in order to enhance the
ﬂuorescence intensity for all studied drugs.
It was observed that, the ﬂuorescence intensity of Los-K at
the pH range 2–2.5 was increased about 10% in comparison to
the results obtained with citric acid. After that, gradual
decrease in the intensity occurred till pH 7. Consequently,
pH 2.3 of this buffer system was chosen as the optimum milieu
for determination of Los-K.
In the case of Cand, the relative ﬂuorescence intensity was
increased about 25% over the pH range from 3 to 4.5 of this
buffer system than the obtained RFI in citric acid. Before and
after this pH range, the intensity of ﬂuorescence was markedly
decreased so, pH 3.5 was selected as the best medium for
determination of Cand.
The relative ﬂuorescence intensity of Irb and Val measured
at pH 2, was decreased about 13% and 22%, respectively, in
comparison to using 0.5 M HCl as milieu for their determina-
tion, followed by marked decrease till pH 7.
Upon changing the constitution of the buffer system in
order to increase the intensity of ﬂuorescence, two other buffer
systems such as Clark and Lubs buffer (0.1 M potassium
bi-phthalate, 0.1 M HCl and 0.1 M NaOH) (pH range 2.2–6.0)
and McIlavine buffer (0.2 M disodium hydrogen phosphate
and 0.1 M citric acid) (pH range 2.2–7.0) [30] were
investigated.
Complete quenching of the ﬂuorescence intensity for all
studied drugs was attained using Clark and Lubs buffer (pH
range 2.2–6.0). This was probably owing to potassium bi-
phthalate-containing buffer, which may quench the ﬂuores-
cence of the studied drugs and so this buffer system should be
omitted.
When measurements were made using McIlavine buffer in
the pH range 2.2–7.0, marked decrease in the ﬂuorescence
intensity was obtained for all studied drugs in comparison to
Teorell and Stenhagen buffer.
As a result of this study, the ﬂuorescence intensities were
performed in Teorell and Stenhagen Buffer at pH 2.3 or 3.5
for either Los-K or Cand, respectively, while 0.5 M HCl was
adopted for determination of both Irb and Val.3.1.4. Effect of temperature and time
In order to examine the effect of temperature and heating time
on the native ﬂuorescence in the selected media for each studied
drug, heating was carried out at different temperatures (40, 60,
80 and 100 1C) in a thermostatically controlled water bath for
periods ranging from 1 to 5 min. Sharp decrease in the
ﬂuorescence intensity was obtained immediately upon raising
the temperature over the room temperature. Therefore, measure-
ments were performed at room temperature, for all studied drugs
and the ﬂuorescence was stable for at least 30 min.
3.2. Spectral characteristics
Under the optimum experimental conditions, the best selected
medium for the highest ﬂuorescence intensity was Teorell and
Stenhagen buffer at pH 2.3 and 3.5 for Los-K and Cand,
respectively, while Irb and Val were determined in 0.5 M HCl.
Maximum lEx/lEm equal to 260/390 nm, 262/410 nm, 258/430 nm
and 260/389 nm for Los-K, Irb, Val and Cand, respectively.
In the context of the foregoing discussions, we can relate
these results to the functional groups with acidic–basic proper-
ties such as tetrazole and/or carboxyl group present in the
molecular structures of the studied drugs. The native ﬂuores-
cence behavior may be attributed to deprotonation of tetra-
zole group in all investigated drugs as well as the carboxyl
group in the case of Val. Since the pKa values of the studied
drugs are 3.15, 4.70, 4.90 and 6.00 for Los-K, Irb, Val and
Cand, respectively [29], it is evident that, the best optimum
ﬂuorescence was performed in acids or acidic buffers and that
is exactly proved by this work.
3.3. Calibration curves
Under the speciﬁed conditions, the relationship between the
ﬂuorescence intensity and concentration at the selected excita-
tion and emission wavelengths for each drug was quite linear.
Table 3 shows the most important characteristics and quanti-
tative parameters for all investigated drugs such as slope,
intercept, LOD, LOQ and correlation coefﬁcients.4. Method validation
The proposed method was fully validated according to USP 30
NF25 validation guidelines [3] and complied with the inter-
national conference on harmonization (ICH) guidelines [31].
Table 3 Quantitative parameters for the analysis of the studied drugs by the proposed method.
Drug Range (lg/mL) Correlation
coefﬁcient (r)
Slope (b)7SDa Intercept
(a)7SDa
LODb
(lg/mL)
LOQc
(lg/mL)
Los-k 0.025–1.000 0.9991 860.7176.39 0.2572.08 0.008 0.024
Cand 0.05–1.70 0.9982 433.9072.91 5.2872.54 0.019 0.058
Irb 0.025–1.000 0.9987 855.9377.84 1.5971.92 0.007 0.022
Val 0.006–0.650 0.9985 1514.02713.46 7.6470.78 0.002 0.005
aAverage of ﬁve determinations.
bLOD is the limit of detection.
cLOQ is the limit of quantitation.
Table 4 Precision and accuracy of the proposed method
for the analysis of the studied drugs.
Drug Conc.
(lg/mL)
Recovery (%)7SDa RSDa (%)
Los-K 0.3 101.3671.23 1.32
0.5 98.8370.15 0.39
0.8 100.8371.08 0.98
Irb 0.3 101.5871.25 0.41
0.5 99.8671.02 1.20
0.8 101.4770.72 1.47
S.R. El-Shaboury et al.164.1. Sensitivity
The limit of detection (LOD) and the limit of quantitation
(LOQ) for all the studied drugs were calculated. The small
values of LOD (0.002–0.019 mg/mL) and LOQ (0.005–
0.058 mg/mL) indicate good sensitivity and low background
effect of the proposed method (Table 3). Also the using of
buffer or acid medium in the developed method led to
enhancement in both sensitivity, detection and quantitation
limits at concentration level 20, 13 and 1.6 times better than
the previously reported methods for ﬂuorimetric determina-
tion of Los-K, Irb and Val, respectively [26–28].Val 0.1 100.5470.90 0.94
0.3 98.7571.03 0.49
0.5 99.4570.78 0.85
Cand 0.5 99.3270.88 0.17
1.0 99.4770.97 0.93
1.5 99.8571.66 1.50
SD: Standard deviation.
RSD: Relative standard deviation.
aAverage of ﬁve determinations.4.2. Precision and accuracy
Five determinations at three different concentration levels of
each drug covering low, medium and high concentration of the
linear range were performed. The small value of relative
standard deviation (RSD), indicates high precision of the
method for quantitative determination of the ﬂuorescence
intensity for all studied AIIRA’s. Moreover, the good percen-
tage of recoveries of each standard drug conﬁrms excellent
accuracy (Table 4).4.3. Selectivity
The selectivity of the proposed method for analysis of the
investigated AIIRA’s was carried out to evaluate the effect of
the co-formulated HCTZ and commonly encountered excipi-
ents. The results showed that no interferences could be
observed from the co-formulated HCTZ as well as other
excipients.4.4. Robustness and ruggedness
Robustness of the presented study was evaluated by changing
one experimental parameter of the experimental procedure
while the other parameters were kept constant; the recovery
percentage was calculated each time. The small variations in
any of the variables did not signiﬁcantly affect the results. This
indicates the good reliability of the proposed method.
Ruggedness of the proposed method was assessed by
applying the procedure at different elapsed time. The obtained
results of the proposed method express good reproducibility of
the presented method.5. Applications
The developed method was applied successfully for the
determination of the studied drugs in their pharmaceutical
dosage forms. Five replicate measurements were performed
for each drug either alone or in combination with other active
ingredient HCTZ. The results were validated by comparison
to previously reported methods [22–25]. No signiﬁcant differ-
ence was found by applying t-test and F-test at 95% con-
ﬁdence level, indicating good accuracy and precision of the
proposed method for the analysis of the studied drugs in their
pharmaceutical dosage forms (Table 5).6. Conclusion
The proposed method is simple, precise, accurate spectro-
ﬂuorimetric method for determination of Losartan potassium,
Irbesartan, Valsartan and Candesartan cilexetil. The method
depended on measurements of the relative ﬂuorescence inten-
sity for the studied drugs using acids or buffers. In comparison
to previously reported methods, the sensitivity was enhanced
about 20, 13 or 1.6 times more than these methods.
Table 5 Determination of the studied drug in their pharmaceutical dosage forms (Tablets).
Drug Dosage form (Tablets) Recovery (%)7SDa t-valueb F-valueb Reference
Proposed method Reported method
Los-K Losarmephas 101.3270.75 98.8470.38 1.97 5.05 [22]
Hysartans 98.2570.34 98.8470.44 1.30 3.47 [22]
Irb Aprovels 98.8570.98 100.1370.51 2.44 2.11 [23]
Co-Aprovels 101.1270.48 98.7470.21 1.48 3.90 [23]
Val Taregs 97.4570.37 98.6270.48 2.60 1.62 [24]
Co-Taregs 98.3070.44 99.7070.41 1.10 1.26 [24]
Cand Atacands 100.1270.11 102.2070.59 2.18 4.93 [25]
Atacand Pluss 98.5470.81 100.0470.38 1.92 5.45 [25]
aAverage of ﬁve determinations.
bThe tabulated values of t and F at 95% conﬁdence level are 2.78 and 6.39, respectively.
Spectroﬂuorimetry for determination of AIIRA’s 17The method was applied for the determination of the inves-
tigated drugs in their dosage forms in the presence of
hydrochlorothiazide without interference. Also the statistical
data represent the suitability and reproducibility of the
proposed method for routine analysis in the quality control
laboratories.
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